Introduction
Materials and methods
Peptides and altered peptide ligands
Hybridoma response (SI) | |||||||
---|---|---|---|---|---|---|---|
Compound | HC gp-39 | Sequence | HLA-DR binding IC50 (μM) | 5G11 | 8B12 | 14G11 | 20H5 |
Vβ10b | Vβ10b | Vβ6 | Vβ10b | ||||
1 | 263–275 | RSFTLASSETGVG | 0.12 |
13
|
9
|
15
|
26
|
2 | 263–274 | RSFTLASSETGV
| 0.09 |
7
|
8
|
10
|
22
|
3 | 263–273 | RSFTLASSETG
| 0.20 | 2 |
5
|
5
|
15
|
4 | 263–272 | RSFTLASSET
| 7.0 | 1 | 1 | 1 | 2 |
5 | 264–275 | SFTLASSETGVG
| 0.09 |
12
|
10
|
15
|
27
|
6 | 265–275 | FTLASSETGVG
| 0.11 |
11
|
6
|
8
|
24
|
7 | 266–275 | TLASSETGVG
| >100 | 1 | 1 | 1 |
5
|
8 | 267–275 | LASSETGVG
| >100 | 1 | 1 | 1 | 1 |
9 | 264–274 | SFTLASSETGV
| 0.12 | ND |
7
|
13
|
22
|
Hybridoma response (SI) | |||||||
---|---|---|---|---|---|---|---|
Compound | HC gp-39 | Sequence | HLA-DR binding IC50 (μM) | 5G11 | 8B12 | 14G11 | 20H5 |
1 | 263–275 | RSFTLASSETGVG | 0.08 |
17
|
39
|
30
|
5
|
10 | R263A1 | ASFTLASSETGVG | 0.10 |
23
|
42
|
28
|
5
|
11 | S264A2 | RAFTLASSETGVG | 0.10 |
21
|
43
|
32
|
5
|
12 | F265A3 | RSATLASSETGVG | >35 | 2 |
6
| 2 |
4
|
13 | T266A4 | RSFALASSETGVG | 0.06 |
7
|
14
| 1 |
5
|
14 | L267A5 | RSFTAASSETGVG | 0.08 |
4
| 1 | 1 |
4
|
15 | A268D6 | RSFTLDSSETGVG | 0.24 | 1 | 1 | 1 | 2 |
16 | S269A7 | RSFTLAASETGVG | 0.05 | 2 | 1 | 1 | 2 |
17 | S270A8 | RSFTLASAETGVG | 0.05 |
21
|
29
|
27
|
5
|
18 | E271A9 | RSFTLASSATGVG | 0.04 | 1 | 1 | 1 | 2 |
19 | T272A10 | RSFTLASSEAGVG | 0.04 | 1 |
4
| 1 | 1 |
20 | G273A11 | RSFTLASSETAVG | 0.05 |
7
|
32
|
6
|
5
|
21 | V274A12 | RSFTLASSETGAG | 0.06 |
26
|
40
|
30
|
5
|
22 | G275A13 | RSFTLASSETGVA | 0.05 |
17
|
30
|
20
|
5
|
23 | A3/A8 | RSATLASAETGVG | >36 | ND | ND | ND | ND |
MHC peptide binding assay
Generation and characterization of T cell hybridomas from HLA-DR4(B1*0401) transgenic mice
Molecular modelling of the HLA-DR4(B1*0401)/HC gp-39(263–275) complex
Immunization of HLA-DR4trg mice with WT peptide or APL
Results
Hybridoma characterization: TCR Vβ usage and core epitope mapping
Identification of MHC and TCR contact residues using four different T cell hybridomas
Analysis of the polyclonal response to HC gp-39(263–275) in vivo
Concentration (pg/ml) | |||||||
---|---|---|---|---|---|---|---|
Compound | HC gp39 | Sequence | [Peptide] (μg/ml) | Prol (SI) | MIP1α | RANTES | IFNγ |
1 | 263–275 | RSFTLASSETGVG | 10 |
8
|
252
|
23
|
16
|
2 |
6
|
128
|
13
| 6 | |||
0.4 |
3
| 25 | 6 | <5 | |||
12 | F265A3 | RSATLASSETGVG | 10 |
3
| 27 | 9 | <5 |
2 | 1 | <24 | <6 | <5 | |||
13 | T266A4 | RSFALASSETGVG | 10 |
7
|
116
|
18
|
9
|
2 |
4
|
47
|
11
| <5 | |||
14 | L267A5 | RSFTAASSETGVG | 10 |
7
|
295
|
32
|
14
|
2 |
6
|
112
|
11
| <5 | |||
15 | A268D6 | RSFTLDSSETGVG | 10 |
3
| 29 | <6 | <5 |
2 | 1 | <24 | <6 | <5 | |||
16 | S269A7 | RSFTLAASETGVG | 10 | 2 | <24 | <6 | <5 |
2 | 2 | <24 | <6 | <5 | |||
17 | S270A8 | RSFTLASAETGVG | 10 |
7
|
279
|
20
|
12
|
2 |
5
|
86
|
12
| <5 | |||
18 | E271A9 | RSFTLASSATGVG | 10 | 1 | <24 | <6 | <5 |
2 | 1 | <24 | <6 | <5 | |||
19 | T272A10 | RSFTLASSEAGVG | 10 | 1 | <24 | <6 | <5 |
2 | 1 | <24 | <6 | <5 | |||
20 | G273A11 | RSFTLASSETAVG | 10 |
4
|
47
|
15
| <5 |
2 | 1 | <24 | <6 | <5 | |||
No peptide | 0 | 1 | <24 | <6 | <5 |